English, Article edition: Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors: In the Management of Acute Coronary Syndromes Nick Bosanquet; Bengt Jonsson; Keith A.A. Fox

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94746
Physical Description
  • article
Language
  • English

Edition details

Title
  • Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/​IIIa Inhibitors: In the Management of Acute Coronary Syndromes
Author
  • Nick Bosanquet
  • Bengt Jonsson
  • Keith A.A. Fox
Physical Description
  • article
Notes
  • The most well established antithrombotic treatment for acute coronary syndromes (ACS) is unfractionated heparin (UFH) plus aspirin, but such treatment may not prevent arterial thrombotic events. Low molecular weight heparins (LMWHs) and platelet glycoprotein (GP) IIb/​IIIa inhibitors offer alternative or adjunctive treatments. However, before these alternatives with higher acquisition costs are accepted in today This paper reviews international pharmacoeconomic studies on the use of LMWHs and GP IIb/​IIIa inhibitors in patients with ACS in an attempt to determine whether these therapies are cost effective. Most of the studies on LMWHs have been cost-minimisation analyses and have focused on enoxaparin sodium, because this is the only LMWH proven to be superior to UFH. Several analyses show that, compared with UFH plus aspirin, enoxaparin sodium provides cost savings both during hospitalisation (30 days) and 1-year follow-up. These cost savings are mainly attributable to fewer cardiac interventions, shorter hospital stays and lower administrative costs. Indeed, the clinical and economic advantages of enoxaparin sodium have led to its recommendation in recent guidelines as the antithrombotic agent of choice for coronary artery disease. Most of the economic analyses of GP IIb/​IIIa inhibitors have been cost-effectiveness analyses. Such analyses indicate that the high acquisition costs of these drugs may be at least partially offset by reductions in other costs if a noninvasive approach to risk stratification is used. Furthermore, use of GP IIb/​IIIa inhibitors appears to give favourable cost-effectiveness ratios compared with other accepted therapies, such as fibrin-specific thrombolytic therapy, in the cardiovascular field, particularly in high-risk patients and those undergoing percutaneous coronary intervention. However, more comprehensive economic data on the GP IIb/​IIIa inhibitors are needed.
  • Acute-coronary-syndromes, Cost-analysis, GPIIb-IIIa-antagonists, Low-molecular-weight-heparins
  • RePEc:wkh:phecon:v:21:y:2003:i:16:p:1135-1152
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment